| Type | Title | Date Released | |
|---|---|---|---|
8-K | OSR Health Provides Shareholder Update Following Nasdaq Panel Decision | ||
8-K | OSR Health Enters Amendment No. 1 to License Agreement, Introducing Convertible Note Option | ||
8-K | Dr. Constance Hoefer Resigns as Chief Scientific Officer of OSR Health, Inc. | ||
8-K | OSR Health, Inc. Schedules Nasdaq Hearings Panel Date to Appeal Delisting | ||
8-K | OSR Health, Inc. Requests Nasdaq Hearing to Appeal Delisting Determination | ||
8-K | OSR Health Receives Nasdaq Staff Delisting Determination; Intends to Request Hearings Panel Appeal | ||
SCHEDULE 13G/A | joint protein central inc. (Filed by) | ||
10-Q | Form 10-Q | ||
8-K | OSR Health, Inc. Announces Results of 2026 Annual Meeting of Stockholders | ||
8-K | OSR Health Issues Clarification Regarding Nasdaq Communication and Shareholder Loyalty CVR Program | ||
8-K | OSR Health Secures Nasdaq Communication: Loyalty CVR Program Will Not Trigger a Price Adjustment | ||
DEF 14A | Form DEF 14A |